Stage I Testicular Seminoma: A SEER Analysis of Contemporary Adjuvant Radiotherapy Trends

    loading  Checking for direct PDF access through Ovid

Abstract

Purpose:

Patients with clinical stage I testicular seminoma have historically been treated with adjuvant radiotherapy in the United States. However, nearly 80% of patients on surveillance will not experience relapse and even with relapse, salvage rates approach 100%. It remains unclear how practice patterns have changed with recently accumulating evidence and changes in guidelines. In a population based setting we evaluated contemporary trends and factors that may affect the use of adjuvant radiotherapy.

Materials and Methods:

A total of 8,151 men diagnosed with stage I testicular seminoma from 2000 to 2009 were identified in the national SEER (Surveillance, Epidemiology, and End Results) registry. A multivariate regression model was constructed to analyze the association of year, age, race, socioeconomic status, SEER region, pathological stage and tumor size with the administration of adjuvant radiotherapy.

Results:

The use of adjuvant radiotherapy decreased significantly from 2000 to 2009. In 2000, 74.7% of patients received radiation, compared with only 37.7% of patients in 2009 (p <0.0001). Later year of diagnosis was significantly associated with decreased odds of receiving adjuvant radiotherapy (p <0.0001, 2000 to 2005 vs 2006 to 2009, OR 0.40, 95% CI 0.36–0.44). Men age 35 years or older (p <0.0002, OR 1.20, 95% CI 1.09–1.32) and men in the highest socioeconomic index quartile (p <0.0001, OR 1.34, 95% CI 1.16–1.54) were more likely to receive adjuvant radiotherapy.

Conclusions:

The use of adjuvant radiotherapy for clinical stage I testicular seminoma has decreased significantly in the last decade. Older age and higher socioeconomic status are associated with higher rates of adjuvant radiotherapy.

Related Topics

    loading  Loading Related Articles